Effect of alfacalcidol on the pulmonary function of adult asthmatic patients: A randomized trial

Publication date: Available online 1 April 2017
Source:Annals of Allergy, Asthma & Immunology
Author(s): Amani M. Ali, Samah Selim, Maggie M. Abbassi, Nirmeen A. Sabry
BackgroundDespite the use of alfacalcidol in the management of corticosteroid-induced osteoporosis, it has never been considered an adjunct treatment for asthma management. It can target vitamin D deficiency, a possible risk factor for asthma, and, hence, improve pulmonary function of patients with asthma.ObjectiveTo explore the effect of alfacalcidol administration on pulmonary function and study the pattern of vitamin D deficiency in adults with asthma in Egypt.MethodsSerum 25-hydroxyvitamin D was measured in 115 adults: 33 healthy subjects and 82 patients with asthma. Then, patients with asthma were randomized to receive standard asthma treatment only (n = 39) or receive it in addition to 1 μg of alfacalcidol daily for 4 months (n = 43). Randomization was stratified by the stage of asthma severity. Spirometry and measurement of 25-hydroxyvitamin were performed at baseline and end of follow-up.ResultsVitamin D deficiency was more common in patients with asthma (57.3%) than in healthy subjects (21.2%; P < .001). In patients with asthma, alfacalcidol significantly improved forced expiratory volume in the first second and forced vital capacity (P < .001 for the 2 tests). Moreover, more patients in the intervention arm showed improvement in asthma severity stage (P = .04). A nonsignificant difference was observed in improvement of forced expiratory volume in the first second between patients with vitamin D deficiency and those without deficiency in the intervention group (P > .05).ConclusionAlfacalcidol supplementation improved the pulmonary function and severity stage of adult patients with asthma regardless of deficiency.Trial RegistrationClinicalTrials.gov Identifier: NCT02747381.



http://ift.tt/2nsJDfh